(5/4) reports, "Abbott Laboratories will spend $110 million to buy a
potential kidney treatment from the privately held Danish company Action
Pharma, the company said Thursday. The drug, labeled AP214, is in
mid-stage clinical testing and is designed to prevent acute kidney
injury in patients undergoing major cardiac surgery," by reducing
"systemic inflammation and cellular death caused by a lack of blood
flow."
No comments:
Post a Comment